SANSURE BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.33 CNY | -0.33% |
|
-1.35% | -6.24% |
| Feb. 29 | Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84% | MT |
| Feb. 28 | Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 10.49B 76.01B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
43.6
x | P/E ratio 2025 * |
28.2
x | Employees | 2,567 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.34% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.33% | ||
| 1 week | -1.35% | ||
| Current month | -5.03% | ||
| 1 month | -11.45% | ||
| 3 months | +3.97% | ||
| 6 months | +19.03% | ||
| Current year | -6.24% |
1 week
17.93
18.62
1 month
17.9320.85
Current year
16.0822.00
1 year
14.7223.35
3 years
14.7275.44
5 years
14.72105.10
10 years
14.72105.10
| Managers | Title | Age | Since |
|---|---|---|---|
Li Zhong Dai
CEO | Chief Executive Officer | 56 | 08-04-22 |
Wu Tan
CHM | Chairman | 40 | 09-12-31 |
Zhu Peng
DFI | Director of Finance/CFO | 48 | 17-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shan Ping Wang
BRD | Director/Board Member | 60 | 16-06-30 |
Li Zhong Dai
CEO | Chief Executive Officer | 56 | 08-04-22 |
Xia Lin Yu
BRD | Director/Board Member | 45 | 08-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.04% | 1 M€ | -11.87% | - | |
| 0.12% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 18.33 | -0.33% | 3,164,371 |
| 24-04-19 | 18.39 | +0.33% | 2,524,284 |
| 24-04-18 | 18.33 | +0.44% | 4,066,461 |
| 24-04-17 | 18.25 | +0.33% | 5,440,224 |
| 24-04-16 | 18.19 | -2.10% | 6,076,596 |
End-of-day quote Shanghai S.E., April 21, 2024
More quotes
Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.
Calendar
2024-04-22
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.24% | 1.45B | |
| +1.19% | 12.66B | |
| -17.03% | 7.04B | |
| +1.24% | 5.39B | |
| -2.51% | 4.45B | |
| +1.73% | 4.32B | |
| -50.32% | 3.31B | |
| +6.90% | 2.6B | |
| -17.21% | 2.01B | |
| -3.40% | 1.67B |
- Stock Market
- Equities
- 688289 Stock
